Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Pages: 62 Published: June 13, 2022 Report Code: GDHC066CL

  • Overview
  • Contents
  • FAQ
  • Listen
    iSpeech.org

The Rosacea pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for rosacea. The report also analyzes the clinical and commercial landscapes of rosacea, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Rosacea is a chronic relapsing inflammatory skin disease characterized by immune dysfunction and neurovascular dysregulation. Though its pathophysiologic connections remain to be defined, there are numerous studies showing association of rosacea with chronic inflammatory conditions including inflammatory cytokines and metabolic, immune, and endocrine changes.

Which are the key regions in the Rosacea pipeline drugs market?

The key regions in the Rosacea pipeline drugs market are Asia-Pacific, Europe, Middle Eat & Africa, South & Central America. Single-country trials dominated in rosacea globally over the past 10 years, with highest number of trials registered in North America.

Rosacea pipeline drugs market, by regions

Rosacea pipeline drugs market, by regions

For more region insights, download a free report sample

Which are the key development stages in the Rosacea pipeline drugs market?

The key development stages in the Rosacea pipeline drugs market are phase II, phase III, phase I, and preclinical. Preclinical stage has the highest share in the Rosacea pipeline drugs market.

Rosacea pipeline drugs market, by development stage

Rosacea pipeline drugs market, by development stage

For more development stage insights, download a free report sample

Which are the key molecule types in the Rosacea pipeline drugs market?

The key molecule types in the Rosacea pipeline drugs market are small molecule, and biologic. The majority of drugs with a known molecule type in development for the treatment of rosacea are small molecules.

Rosacea pipeline drugs market, by molecule types

Rosacea pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key MoA in the Rosacea pipeline drugs market?

The key MoA in the Rosacea pipeline drugs market are genes, nucleic acid, & related components inhibitor, enzyme inhibitor, receptor antagonist, receptor inhibitor, cells and cells organelle disrupter, protein and peptide inhibitor. Most of the molecules undergoing development for rosacea with a known mechanism of action are inhibitors of genes, nucleic acids, and related components.

Rosacea pipeline drugs market, by MoA

Rosacea pipeline drugs market, by MoA

For more MoA insights, download a free report sample

Which are the key RoA in the Rosacea pipeline drugs market?

The key RoA in the Rosacea pipeline drugs market are topical, oral, injection, and inhalational. Inhalational has the highest share in the Rosacea pipeline drugs market.

Rosacea pipeline drugs market, by RoA

Rosacea pipeline drugs market, by RoA

For more RoA insights, download a free report sample

Which are the key sponsors in the Rosacea pipeline drugs market?

The key sponsors in the Rosacea pipeline drugs market are Galderma SA, Allergan Ltd, Cutanea Life Sciences Inc, So-Gel Technologies Inc, Foamix Pharmaceuticals Ltd, Amorepacific Corp, Padagis LLC, and others.

Rosacea pipeline drugs market, by sponsors

Rosacea pipeline drugs market, by sponsors

To know more about sponsors, download a free report sample

Market report overview

Key regions Asia-Pacific, Europe, Middle Eat & Africa, South & Central America
Key development stages Phase II, Phase III, Phase I, And Preclinical
Key molecule types Small Molecule, and Biologic
Genes, Nucleic Acid, & Related Components Inhibitor, Enzyme Inhibitor, Receptor Antagonist, Receptor Inhibitor, Cells and Cells Organelle Disrupter, Protein and Peptide Inhibitor
Key RoA Topical, Oral, Injection, and Inhalational
Key sponsors Galderma SA, Allergan Ltd, Cutanea Life Sciences Inc, So-Gel Technologies Inc, Foamix Pharmaceuticals Ltd, Amorepacific Corp, and Padagis LLC

Scope

GlobalData’s Rosacea: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Rosacea market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Rosacea market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

5 Pipeline Drugs Assessment

5.1 Late-stage Pipeline Drugs

5.2 Overview by Development Stage

5.3 Overview by Molecule Type

5.4 Overview by Mechanism of Action

5.5 Overview by Route of Administration

5.6 Therapy Area and Indication-specific PTSR and LoA

5.7 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6 Clinical Trials Assessment

6.1 Historical Overview

6.2 Overview by Phase

6.3 Overview by Status

6.4 Overview by Phase for Ongoing and Planned Trials

6.5 Trials with Virtual Components

6.6 Geographic Overview

6.7 Single-Country and Multinational Trials by Region

6.8 Top 20 Sponsors with Breakdown by Phase

6.9 Top 20 Sponsors with Breakdown by Status

6.10 Overview by Endpoint Status

6.11 Overview by Race and Ethnicity

6.12 Enrollment Data

6.13 Top 20 countries for Trial Sites

6.14 Top 20 Sites Globally

6.15 Feasibility Analysis – Geographic Overview

6.16 Feasibility Analysis – Benchmark Models

7 Deals Landscape

7.1 Mergers, Acquisitions, and Strategic Alliances by Region

7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

10.1 Methodology

10.2 Methodology – PTSR and LoA Analysis

10.3 About the Authors

10.4 Contact Us

10.5 Disclaimer

Frequently Asked Questions

The key regions in the Rosacea pipeline drugs market are Asia-Pacific, Europe, Middle Eat & Africa, South & Central America. Single-country trials dominated in rosacea globally over the past 10 years, with highest number of trials registered in North America.

The key development stage in the Rosacea pipeline drugs market are phase II, phase III, phase I, and preclinical. Preclinical stage has the highest share in the Rosacea pipeline drugs market.

The key molecule types in the Rosacea pipeline drugs market are small molecule, and biologic. The majority of drugs with a known molecule type in development for the treatment of rosacea are small molecules.

The key MoA in the Rosacea pipeline drugs market are genes, nucleic acid, & related components inhibitor, enzyme inhibitor, receptor antagonist, receptor inhibitor, cells and cells organelle disrupter, protein and peptide inhibitor. Most of the molecules undergoing development for rosacea with a known mechanism of action are inhibitors of genes, nucleic acids, and related components.

The key RoA in the Rosacea pipeline drugs market are topical, oral, injection, and inhalational. Inhalational has the highest share in the Rosacea pipeline drugs market.

The key sponsors in the Rosacea pipeline drugs market are Galderma SA, Allergan Ltd, Cutanea Life Sciences Inc, So-Gel Technologies Inc, Foamix Pharmaceuticals Ltd, Amorepacific Corp, Padagis LLC, and others.

$3495

Can be used by individual purchaser only

$10485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.